Cancer Immunotherapy Market Share Analysis Report, 2022-2030
The global Cancer Immunotherapy market size was estimated at USD 82.10 billion in 2021 and is expected to surpass around USD 261.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 13.11% during the forecast period 2022 to 2030.
Overview of Global Cancer Immunotherapy Market
Immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. It is a kind of biological treatment. Biological therapy makes use of compounds derived from biological creatures or lab-created copies of these substances.
Increase in R&D activities, improvements in efficacy & accuracy of newer medicines, surge in adoption of target therapy over standard therapy, and rise in prevalence of cancer are the major factors propelling the global cancer immunotherapy market. In addition, rise in incidence of cancer is a key factor driving the global cancer immunotherapy market. In the U.S., cancer is the biggest cause of mortality and disease, and it not only has a significant effect on the health of patients and survivors, but also has a major financial impact.
Several companies are increasingly investing in R&D activities to develop more effective treatments for cancer. For instance, TILT Bio therapeutics has announced over $10 million financing to the oncology immunotherapy assets. Companies such as Justin Wilson, partner & attorney at Withers & Rodgers, have discussed their opinion on innovations in the microbe in supporting the discovery of new drugs & treatments in the immunotherapy market.
Report Scope of the Cancer Immunotherapy Market
|
Report Coverage |
Details |
|
Market Size |
USD 261.9 Billion by 2030 |
|
Growth Rate |
CAGR of 13.11% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Therapy Type, Therapeutic Area, End-user And Geography, |
|
Companies Mentioned |
|
Popularity of Cancer Immunotherapy Treatment among Patients Due to Cost-effectiveness and Less Side Effects
In terms of therapy type, the global cancer immunotherapy market has been classified into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Monoclonal antibodies have been the treatment method of choice for a large segment of the global healthcare industry, giving it a significant advantage over other segments. Monoclonal antibodies have gained, as it is less expensive than other therapies. However, the global cancer immunotherapy market is expected to witness increase in demand for immune checkpoint inhibitors due to higher success rates and overall efficiency.
Based on therapeutic area, the global cancer immunotherapy market has been categorized into blood cancer, prostate cancer, melanoma, breast cancer, lung cancer, colorectal cancer, and other minor cancers. Breast cancer has been the most common target for immunotherapy. Increase in population of smokers and rise in total air pollution in metropolitan areas drive the lung cancer segment.
Rise in R&D Activities and High Efficacy of Newer Therapies to Augment Market
Rise in R&D activities in the field of cancer immunotherapy has led to the introduction of advanced variants with improved treatment efficacy and effectiveness. Immuno oncology has shown promising results in terms of increased survival and decreased toxicity. The market is likely to be propelled by a paradigm shift from traditional chemotherapies to immunotherapies. Immunotherapies in development are expected to offer more treatment options and better outcomes than currently available therapies. The introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, aimed at multiple myeloma receptors, is projected to propel the global market. The market is likely to be driven by ongoing research on similar drugs with the goal of reducing side effects.
Monoclonal Antibodies to Remain Dominant Immunotherapeutic Drugs in Global Market
In terms of therapy type, the global cancer immunotherapy market has been classified into monoclonal antibodies, immune checkpoint inhibitors, PD-1/PD-L1, CTLA-4, immune system modulators, cancer vaccines, and others. The monoclonal antibody segment accounted for key market share in 2021. Monoclonal antibodies are the most commonly prescribed immunotherapeutic drugs in the world. Following Amgen's approval of Blincyto (blinatumomab), a bispecific antibody that targets B-cell lymphoblastic leukemia, monoclonal antibodies were developed as effective immunotherapeutic options.
Increase in research & development on the use of monoclonal bodies as naked antigen binding antibodies, conjugated antibodies, and bispecific antibodies has led to the discovery of new cancer therapeutic options.
High Cost of Cancer Immunotherapy Manufacturing R&D to Hamper Global Market Growth
The global cancer immunotherapy market is concerned about both research and manufacturing costs as well as market price for the end-user. For a developing organization, cancer immunotherapy research & development requires large amounts of resources, which raises worries about receiving finances. Research activities involving new technology development require significant investment, which is expected to be received with significant profits by the innovator. Cancer immunotherapy is a niche segment and requires high investment. This deters companies to enter the market due to uncertainty of receiving expected profit.
Regional Outlook of Global Cancer Immunotherapy Market
In terms of region, the global cancer immunotherapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is projected to be a highly lucrative market for cancer immunotherapy during the forecast period. Well-established healthcare infrastructure and increase in government initiatives are the major factors driving the market in the region. North America's large market share can be attributed to rise in number of patients suffering from cancer, increase in adoption rate of immunotherapy, and development of bioinformatics tools that enhance the drug development process.
The market in Asia Pacific is expected to experience the fastest growth during the forecast period. New and advanced immunotherapy drugs have been introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies. Approval of new treatment drugs in China and Japan boosts the adoption of immunotherapy for treatment of tumors.
Analysis of Key Players in Global Cancer Immunotherapy Market
This report profiles major players in the global cancer immunotherapy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global cancer immunotherapy market is quite competitive, with the top players accounting for major share of the market and companies focusing on research & development to produce better pharmaceutical products for the existing diseases.
Leading players operating in the global cancer immunotherapy market are Amgen, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, Janssen Biotech, Inc., Merck & Co., Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.
Key Developments in Global Cancer Immunotherapy Market
Key players in the global cancer immunotherapy market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cancer immunotherapy market. A few expansion strategies adopted by players operating in the global cancer immunotherapy market are:
Some of the prominent players in the Cancer Immunotherapy Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cancer Immunotherapy market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Immunotherapy Market Analysis and Forecast, 2017–2030
5. Key Insights
5.1. Value Chain Analysis
5.2. Pipeline Analysis
5.3. Cancer Epidemiology
5.4. COVID-19 impact
6. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2017–2030
6.3.1. Monoclonal Antibodies
6.3.2. Immune Checkpoint Inhibitors
6.3.3. PD-1/PD-L1
6.3.4. CTLA-4
6.3.5. Immune System Modulators
6.3.6. Cancer Vaccines
6.3.7. Others
6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2017–2030
7.3.1. Lung Cancer
7.3.2. Colorectal Cancer
7.3.3. Breast Cancer
7.3.4. Prostate Cancer
7.3.5. Melanoma
7.3.6. Blood Cancer
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Global Cancer Immunotherapy Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2030
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers (ASCs)
8.3.3. Cancer Research Centers
8.3.4. Clinics
8.4. Market Attractiveness Analysis, by End-user
9. Global Cancer Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2017–2030
10.2.1. Monoclonal Antibodies
10.2.2. Immune Checkpoint Inhibitors
10.2.3. PD-1/PD-L1
10.2.4. CTLA-4
10.2.5. Immune System Modulators
10.2.6. Cancer Vaccines
10.2.7. Others
10.3. Market Value Forecast, by Therapeutic Area, 2017–2030
10.3.1. Lung Cancer
10.3.2. Colorectal Cancer
10.3.3. Breast Cancer
10.3.4. Prostate Cancer
10.3.5. Melanoma
10.3.6. Blood Cancer
10.3.7. Others
10.4. Market Value Forecast, by End-user, 2017–2030
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers (ASCs)
10.4.3. Cancer Research Centers
10.4.4. Clinics
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Therapy Type
10.6.2. By Therapeutic Area
10.6.3. By End-user
10.6.4. By Country
11. Europe Cancer Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2017–2030
11.2.1. Monoclonal Antibodies
11.2.2. Immune Checkpoint Inhibitors
11.2.3. PD-1/PD-L1
11.2.4. CTLA-4
11.2.5. Immune System Modulators
11.2.6. Cancer Vaccines
11.2.7. Others
11.3. Market Value Forecast, by Therapeutic Area, 2017–2030
11.3.1. Lung Cancer
11.3.2. Colorectal Cancer
11.3.3. Breast Cancer
11.3.4. Prostate Cancer
11.3.5. Melanoma
11.3.6. Blood Cancer
11.3.7. Others
11.4. Market Value Forecast, by End-user, 2017–2030
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers (ASCs)
11.4.3. Cancer Research Centers
11.4.4. Clinics
11.5. Market Value Forecast, by Country/Sub-region, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Therapy Type
11.6.2. By Therapeutic Area
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017–2030
12.2.1. Monoclonal Antibodies
12.2.2. Immune Checkpoint Inhibitors
12.2.3. PD-1/PD-L1
12.2.4. CTLA-4
12.2.5. Immune System Modulators
12.2.6. Cancer Vaccines
12.2.7. Others
12.3. Market Value Forecast, by Therapeutic Area, 2017–2030
12.3.1. Lung Cancer
12.3.2. Colorectal Cancer
12.3.3. Breast Cancer
12.3.4. Prostate Cancer
12.3.5. Melanoma
12.3.6. Blood Cancer
12.3.7. Others
12.4. Market Value Forecast, by End-user, 2017–2030
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers (ASCs)
12.4.3. Cancer Research Centers
12.4.4. Clinics
12.5. Market Value Forecast, by Country/Sub-region, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Therapy Type
12.6.2. By Therapeutic Area
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Cancer Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017–2030
13.2.1. Monoclonal Antibodies
13.2.2. Immune Checkpoint Inhibitors
13.2.3. PD-1/PD-L1
13.2.4. CTLA-4
13.2.5. Immune System Modulators
13.2.6. Cancer Vaccines
13.2.7. Others
13.3. Market Value Forecast, by Therapeutic Area, 2017–2030
13.3.1. Lung Cancer
13.3.2. Colorectal Cancer
13.3.3. Breast Cancer
13.3.4. Prostate Cancer
13.3.5. Melanoma
13.3.6. Blood Cancer
13.3.7. Others
13.4. Market Value Forecast, by End-user, 2017–2030
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers (ASCs)
13.4.3. Cancer Research Centers
13.4.4. Clinics
13.5. Market Value Forecast, by Country/Sub-region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Therapy Type
13.6.2. By Therapeutic Area
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017–2030
14.2.1. Monoclonal Antibodies
14.2.2. Immune Checkpoint Inhibitors
14.2.3. PD-1/PD-L1
14.2.4. CTLA-4
14.2.5. Immune System Modulators
14.2.6. Cancer Vaccines
14.2.7. Others
14.3. Market Value Forecast, by Therapeutic Area, 2017–2030
14.3.1. Lung Cancer
14.3.2. Colorectal Cancer
14.3.3. Breast Cancer
14.3.4. Prostate Cancer
14.3.5. Melanoma
14.3.6. Blood Cancer
14.3.7. Others
14.4. Market Value Forecast, by End-user, 2017–2030
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers (ASCs)
14.4.3. Cancer Research Centers
14.4.4. Clinics
14.5. Market Value Forecast, by Country/Sub-region, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Therapy Type
14.6.2. By Therapeutic Area
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Analysis
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Analysis
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Bristol-Myers Squibb Company
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Analysis
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Analysis
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Spectrum Pharmaceuticals
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Analysis
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. GlaxoSmithKline plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Analysis
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Analysis
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. AstraZeneca plc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Analysis
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Eli Lilly and Company.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Analysis
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Takeda Pharmaceuticals
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Analysis
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers